Long-acting PASylated leptin ameliorates obesity by promoting satiety and preventing hypometabolism in leptin-deficient Lepob/ob mice

Endocrinology

Volumn 157, Issue 1, 2016, Pages 233-244

  Bolze, Florian ^a   Morath, Volker ^a   Bast, Andrea ^a   Rink, Nadine ^a   Schlapschy, Martin ^a   Mocek, Sabine ^a   Skerra, Arne ^a,b   Klingenspor, Martin ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b XL Protein GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; ALANINE; ALANINE AMINOTRANSFERASE; INSULIN; LEPTIN; NEUROPEPTIDE Y; PROLINE; RECOMBINANT LEPTIN; SERINE; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCOUPLING PROTEIN 1; ANOREXIGENIC AGENT; HYBRID PROTEIN; PEPTIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BODY COMPOSITION; BODY TEMPERATURE; BROWN ADIPOSE TISSUE; CALORIMETRY; CONTROLLED STUDY; DIET RESTRICTION; ENERGY BALANCE; ENERGY EXPENDITURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; FOOD INTAKE; GENE EXPRESSION; GLOMERULUS FILTRATION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HYPOTHALAMUS; HYPOTHERMIA; IMMUNOGENICITY; INSULIN BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PRIORITY JOURNAL; SATIETY; WEIGHT REDUCTION; WESTERN BLOTTING; WHITE ADIPOSE TISSUE; ANALOGS AND DERIVATIVES; ANIMAL; CALORIC INTAKE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; GERMFREE ANIMAL; METABOLISM; MOLECULAR WEIGHT; MOTOR ACTIVITY; MUTANT MOUSE STRAIN; PATHOLOGY; PROTEIN MOTIF; PSYCHOPHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; THERMOGENESIS;

AMINO ACID MOTIFS; ANIMALS; APPETITE DEPRESSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; HYPOTHALAMUS; INJECTIONS, SUBCUTANEOUS; LEPTIN; LIVER; MALE; MICE, MUTANT STRAINS; MOLECULAR WEIGHT; MOTOR ACTIVITY; OBESITY; PEPTIDES; RECOMBINANT FUSION PROTEINS; SATIETY RESPONSE; SPECIFIC PATHOGEN-FREE ORGANISMS; THERMOGENESIS; WEIGHT LOSS;

EID: 84954566720     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1519     Document Type: Article

References (57)

1. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest. 2011;121:2087-2093.
2. Allison MB, Myers MG Jr. 20 years of leptin: connecting leptin signaling to biological function. J Endocrinol. 2014;223:T25-T35.
3. De Luca C, Kowalski TJ, Zhang Y, et al. Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes. J Clin Invest. 2005;115:3484-3493.
4. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387:903-908.
5. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879-884.
6. Wabitsch M, Funcke JB, Lennerz B, et al. Biologically inactive leptin and early-onset extreme obesity. N Engl J Med. 2015;372:48-54.
7. Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulindeficient type I diabetes. Proc Natl Acad Sci USA. 2010;107:4813-4819.
8. Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci USA. 2011;108:6585-6590.
9. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570-578.
10. Chou K, Perry CM. Metreleptin: first global approval. Drugs. 2013;73:989-997.
11. Cumin F, Baum HP, Levens N. Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord. 1996;20:1120-1126.
12. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540-543.
13. Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. Metabolism. 2015;64:146-156.
14. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22:868-876.
15. Haraldsson B, Sorensson J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci. 2004;19:7-10.
16. Schlapschy M, Binder U, Börger C, et al. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel. 2013;26:489-501.
17. Morath V, Bolze F, Schlapschy M, et al. PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy. Mol Pharm. 2015;12:1431-1442.
18. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered. 1950;41:317-318.
19. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-432.
20. Hwa JJ, Fawzi AB, Graziano MP, et al. Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice. Am J Physiol. 1997;272:R1204-R1209.
21. Mistry AM, Swick AG, Romsos DR. Leptin rapidly lowers food intake and elevates metabolic rates in lean and ob/ob mice. J Nutr. 1997;127:2065-2072.
22. Breslow MJ, Min-Lee K, Brown DR, Chacko VP, Palmer D, Berkowitz DE. Effect of leptin deficiency on metabolic rate in ob/ob mice. Am J Physiol. 1999;276:E443-E449.
23. Levin N, Nelson C, Gurney A, Vandlen R, De Sauvage F. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc Natl Acad Sci USA. 1996;93:1726-1730.
24. Himms-Hagen J. On raising energy expenditure in ob/ob mice. Science. 1997;276:1132-1133.
25. Butler AA, Kozak LP. A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes. Diabetes. 2010;59:323-329.
26. Heldmaier G, Ruf T. Body temperature and metabolic rate during natural hypothermia in endotherms. J Comp Physiol B. 1992;162:696-706.
27. Even PC, Nadkarni NA. Indirect calorimetry in laboratory mice and rats: principles, practical considerations, interpretation and perspectives. Am J Physiol Regul Integr Comp Physiol. 2012;303:R459-R476.
28. Klingenspor M, Ebbinghaus C, Hulshorst G, et al. Multiple regulatory steps are involved in the control of lipoprotein lipase activity in brown adipose tissue. J Lipid Res. 1996;37:1685-1695.
29. Bolze F, Rink N, Brumm H, et al. Characterization of the melanocortin-4-receptor nonsense mutation W16X in vitro and in vivo. Pharmacogenomics J. 2013;13:80-93.
30. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323-340.
31. Steiner M, Bourges HR, Freedman LS, Gray SJ. Effect of starvation on the tissue composition of the small intestine in the rat. Am J Physiol. 1968;215:75-77.
32. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006;21(suppl 5):v9-v12.
33. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008;88:906-912.
34. Ravussin Y, Gutman R, Diano S, et al. Effects of chronic weight perturbation on energy homeostasis and brain structure in mice. AmJ Physiol Regul IntegrCompPhysiol. 2011;300:R1352-R1362.
35. Freeman DA, Lewis DA, Kauffman AS, Blum RM, Dark J. Reduced leptin concentrations are permissive for display of torpor in Siberian hamsters. Am J Physiol Regul IntegrCompPhysiol. 2004;287:R97-R103.
36. Döring H, Schwarzer K, Nuesslein-Hildesheim B, Schmidt I. Leptin selectively increases energy expenditure of food-restricted lean mice. Int J Obes Relat Metab Disord. 1998;22:83-88.
37. Gavrilova O, Leon LR, Marcus-Samuels B, et al. Torpor in mice is induced by both leptin-dependent and -independent mechanisms. Proc Natl Acad Sci USA. 1999;96:14623-14628.
38. Wang MY, Lee Y, Unger RH. Novel form of lipolysis induced by leptin. J Biol Chem. 1999;274:17541-17544.
39. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415:339-343.
40. Huang W, Dedousis N, Bandi A, Lopaschuk GD, O'Doherty RM. Liver triglyceride secretion and lipid oxidative metabolism are rapidly altered by leptin in vivo. Endocrinology. 2006;147:1480-1487.
41. Berglund ED, Vianna CR, Donato J Jr, et al. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest. 2012;122:1000-1009.
42. Koch C, Augustine RA, Steger J, et al. Leptin rapidly improves glucose homeostasis in obese mice by increasing hypothalamic insulin sensitivity. J Neurosci. 2010;30:16180-16187.
43. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603-608.
44. Vitola BE, Deivanayagam S, Stein RI, et al. Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity (Silver Spring). 2009;17:1744-1748.
45. Diaz MB, Herzig S, Vegiopoulos A. Thermogenic adipocytes: from cells to physiology and medicine. Metabolism. 2014;63:1238-1249.
46. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543-546.
47. Koch CE, Lowe C, Pretz D, Steger J, Williams LM, Tups A. High-fat diet induces leptin resistance in leptin-deficient mice. J Neuroendocrinol. 2014;26:58-67.
48. Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA. 2004;101:4531-4536.
49. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537-556.
50. Harari D, Kuhn N, Abramovich R, et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis. J Biol Chem. 2014;289:29014-29029.
51. Verhoef JJ, Carpenter JF, Anchordoquy TJ, Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today. 2014;19:1945-1952.
52. Gegg C, Kinstler O. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility. US Patent. 2002; US6420339B1.
53. Fujikawa T, Chuang JC, Sakata I, Ramadori G, Coppari R. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci USA. 2010;107:17391-17396.
54. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282:1568-1575.
55. Münzberg H. Leptin-signaling pathways and leptin resistance. Forum Nutr. 2010;63:123-132.
56. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA. 2008;105:7257-7262.
57. Clemmensen C, Chabenne J, Finan B, et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes. 2014;63:1422-1427.